MedPath

A preliminary open-labeled pharmacokinetic study to examine the effect of cilastatin on the prevention of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapy

Phase 1
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000030363
Lead Sponsor
Department of Applied Molecular Medicine, Kidney Research Center, Niigata University Graduate School of Medical and Dental Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
9
Inclusion Criteria

Not provided

Exclusion Criteria

1. Those with kidney dysfunction (eGFR<60 mL/min/1.73m2) 2. Those who have diseases or symptoms considered to have an effect on the determination of efficacy or safety 3. Those who received antibiotics, antiviral drugs, or antifungal drugs (except for topical application, eye drops, or nose drops) within 14 days before enrollment 4. Those who are considered not eligible for this study by attending doctors due to any medical reasons

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath